TrialBlood advances2023

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.

Anna B Halpern et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.